Gain Therapeutics Inc. (GANX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Gain Therapeutics Inc. (GANX:NASDAQ), powered by AI.

Current Price
$1.79
Sector
Healthcare
What is the Gain Therapeutics Inc. stock price forecast?

Gain Therapeutics Inc. is currently trading at $1.79. View real-time AI analysis on Alpha Lenz.

What is Gain Therapeutics Inc. insider trading activity?

View the latest insider trading data for Gain Therapeutics Inc. on Alpha Lenz.

What is Gain Therapeutics Inc.'s P/E ratio?

View Gain Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Gain Therapeutics Inc.

NASDAQ · GANX
$1.79+0.04(+2.29%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Gain Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Gain Therapeutics Inc.'s ROE is -155.7%. Explore profitability and growth together.

Ask for details

Company Overview

Gain Therapeutics Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics. At the heart of its operations is the proprietary SEE-Tx platform, which enables the identification of previously undruggable targets across a range of diseases, primarily focusing on rare genetic disorders and neurological conditions. By analyzing structural proteins, the company aims to address unmet medical needs in areas such as neurodegenerative diseases, offering potential breakthroughs in treatment options. Gain Therapeutics’ emphasis on protein misfolding disorders underscores its impact on critical therapeutic areas, significantly influencing drug research and development in the biotech sector. The company's efforts contribute to redefining therapeutic approaches, ensuring its relevance and importance in the competitive landscape of medical innovations. Gain Therapeutics, by leveraging cutting-edge technology, positions itself as a transformative entity in the medical field, driving forward advancements in patient care for complex diseases.

CEOMr. Gene Mack M.B.A.
SectorHealthcare
IndustryBiotechnology
Employees23

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
23Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-115.39%ROA
-155.66%ROE
-107.09%ROIC

Financial Health

$20.84MCash & Cash Equivalents
$-16.58MNet Debt
22.92%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Gain Therapeutics Inc. (ticker: GANX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 23 employees.

The current price is $1.79 with a P/E ratio of -x and P/B of -x.

ROE is -155.66%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Gain Therapeutics Inc. (GANX) Stock Forecast 2026 $1.79 — Price, Financials & Analyst Targets | Alpha Lenz